Efficacy and economics of hormonal therapies for advanced breast cancer

Drugs and Aging

Volumn 19, Issue 6, 2002, Pages 453-463

  Simon, Michael S ^a,c   Ibrahim, Dina ^a   Newman, Lisa ^a   Stano, Miron ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b OAKLAND UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; MEGESTROL; MEGESTROL ACETATE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

BREAST CANCER; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FLUSHING; HEALTH CARE COST; HORMONAL THERAPY; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; SWEATING; THROMBOEMBOLISM; VAGINA DISCHARGE;

EID: 0036350525     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219060-00004     Document Type: Review

References (91)

1. Declining cancer rates in the 1990s
2. Racial differences in breast carcinoma survival
3. Breast cancer therapies in development. A review of their pharmacology and clinical potential
4. Reducing the risk of breast cancer
5. Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials
6. Sentinel lymph node biopsy with metastasis: Can axillary dissection be avoided in some patients with breast cancer?
7. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer
8. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
9. Physical functioning of elderly cancer patients prior to diagnosis and following initial treatment
10. Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996
11. Systemic therapy for older women with breast cancer
12. The biology of breast cancer in older women
13. Clinical pharmacology of selective estrogen receptor modulators
14. Selective estrogen receptor modulators: A look ahead
15. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors
16. Diethylstilbestrol revisited in advanced breast cancer management
17. Pharmacokinetics and pharmacodynamics of medroxyprogestone acetate in advanced breast cancer patients
18. Tamoxifen therapy in primary breast cancer: Biology, efficacy and side effects
19. Use of tamoxifen for breast cancer twenty-eight years later
20. Efficacy of tamoxifen as treatment of breast cancer
21. Treatment of metastatic breast cancer
22. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene
23. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least 2 years
24. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
25. Long term adjuvant tamoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women
26. The question of estrogen replacement therapy in patients with a prior diagnosis of breast cancer
27. Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels
28. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women
29. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen-receptor-positive tumors
30. Controlled trial of tamoxifen as a single adjuvant agent in management of early breast cancer. Analysis at six years by nolvadex adjuvant trial organization
31. Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women
32. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy
33. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients
34. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel P-1 Study
35. Should clinicians be concerned about the carcinogenic potential of tamoxifen?
36. Tamoxifen induced steatohepatitis
37. The effect of tamoxifen on the endometrium
38. Endometrial cancer in tamoxifen treated breast cancer patients. Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
39. Tamoxifen therapy for breast cancer and endometrial cancer risk
40. Toremifene in postmenopausal breast cancer: Efficacy, safety and cost
41. Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: A randomized double-blind, the 'nordic' phase III study
42. Randomized comparison of tamoxifen and two separate does of toremifene in postmenopausal patients with metastatic breast cancer
43. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal patients with breast cancer
44. Multicenter phase II efficacy trial of toremifene in tamoxifen refractory patients with advanced breast cancer
45. Toremifene and tamoxifen in advanced breast cancer - A double-blind crossover trial
46. High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment
47. Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients
48. Re: Effects of the antiestrogenes tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth
49. Safety assessment of tamoxifen and toremifene
50. Treatment of anorexia and weight loss with megestrol acetate in patients with cancer or acquired immunodeficiency syndrome
51. Studies on the mechanism of estrogen biosynthesis. 8. The development of inhibitors of the enzyme system in human placenta
52. New endocrine therapies for breast cancer
53. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer
54. Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: Phase II report
55. Suicide enzyme inhibitors as potential drugs
56. A randomized phase II trial of rogletimide in heavily pretreated breast cancer patients
57. A study of fadrozole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer
58. Two different letrozole doses in the treatment of postmenopausal advanced breast cancer
59. An EORTC breast group phase II study of vorozole (R 83842), a new aromatase inhibitor in advanced breast cancer (ABC)
60. Exemestane in postmenopausal pretreated advanced breast cancer; a multicenter phase II study in patients with aminoglutethimide failure
61. Exemestane improves survival compared with megestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. Results of a double-blind randomised phase III trial
62. Fadrozole versus megestrol acetate: A double-blind randomised trial in advanced breast cancer
63. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials
64. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer in patients
65. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose-effect and improved efficacy and tolerability compared with megestrol acetate
66. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials
67. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
68. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American Multicenter Randomized Trial
69. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group
70. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5,(10)- triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer
71. The incidence and economic costs of cancer, motor vehicle injuries, coronary heart disease, and stroke: A comparative analysis
72. Estimating the treatment costs of breast and lung cancer
73. Counting the costs of cancer therapy
74. The cost of breast cancer recurrences
75. Advanced breast cancer and its prevention by screening
76. The costs of treating breast cancer in Australia and the implications for breast cancer screening
77. Cost of care for cancer in a health maintenance organization
78. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care
79. The costs of cancer to a major employer in the United States: A case-control analysis
80. Cost-effectiveness in oncology
81. The economic potential of tamoxifen prophylaxis in breast cancer
82. Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women
83. Advanced breast cancer: Use of resources and cost implications
84. Anastrozole cost effective in advanced breast cancer
85. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model
86. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results
87. Five-hundred life-saving interventions and their cost-effectiveness
88. Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK
89. Price alert: The official guide to AWP pricing